Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncolog…
| Métrica | EVO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 14.4% | 57.4% | -43.0% |
| Operating Margin | -17.9% | -34.4% | +16.5% |
| Net Margin | -24.6% | -32.5% | +7.9% |
| FCF Margin | -12.4% | -12.6% | +0.1% |
| ROE | -20.6% | -39.2% | +18.6% |
| ROA | -10.3% | -30.9% | +20.7% |
| Current Ratio | 1.98 | 2.73 | -0.75 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -10.3% | — |
| ✓Flujo de caja operativo positivo | €18M | €36M |
| ✗Rentabilidad sobre activos al alza | -10.3% | -3.7% |
| ✓Caja operativa/activos supera al ROA | 1.0% | ROA -10.3% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 1.98 | 1.94 |
| ✓Sin aumentar el nº de acciones | 177M | 177M |
| ✗Margen bruto al alza | 14.4% | 22.4% |
| ✓Rotación de activos al alza | 0.42 | 0.35 |
| Calidad del negocio | FY24 |
|---|---|
| ✗Margen FCF > 10 % | -12.4% |
| ✗ROCE > 10 % | -9.1% |
| ✓Ventas > 5 %/año (3 años) | 8.8% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 21.1% |
Evotec SE cotiza a 1.38 USD y tiene una capitalización bursátil de $490M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud